Quantcast

Latest Pregabalin Stories

2008-10-26 00:00:12

Pfizer will present data on three investigational compounds that represent potential new mechanisms for targeting pain and inflammation. These data will highlight tanezumab, a molecule designed to target nerve growth factor, a key pain mediator; CP-690,550, a JAK-inhibitor that suppresses immune-related inflammatory response; and esreboxetine, a highly-selective norepinephrine reuptake inhibitor which plays a role in controlling the activity of this important neurotransmitter. These data will...

2008-10-07 09:00:14

ANN ARBOR, Mich., Oct. 7, 2008 (GLOBE NEWSWIRE) -- Pipex Pharmaceuticals, Inc. (AMEX:PP), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of central nervous system and autoimmune diseases, today announced that its double-blind, randomized, placebo-controlled phase II clinical trial of oral flupirtine for the treatment of fibromyalgia has received ethics committee approval to initiate the clinical trial. Fibromyalgia is a rheumatic pain...

2008-09-13 12:00:08

By Lois M. Collins Deseret News Understanding of fibromyalgia -- and even its recognition as a legitimate illness -- has come a long way in the past few years. But the most important advance is Food and Drug Administration approval of two drugs to modulate the nerve pain or central nervous pain that marks the illness. That's according to Dr. Lucinda Bateman, a Salt Lake City doctor who was treating the condition long before many of her colleagues had stopped debating whether it's real....

2008-09-12 09:00:09

By Lois M. Collins Deseret News Understanding of fibromyalgia --and even its recognition as a legitimate illness -- has come a long way in the past few years. But the most important advance is Food and Drug Administration approval of two drugs to modulate the nerve pain or central nervous pain that marks the illness. That's according to Dr. Lucinda Bateman, a Salt Lake City doctor who was treating the condition long before many of her colleagues had stopped debating whether it's real....

2008-07-30 12:00:21

UCB has received a not-approvable letter from the FDA for lacosamide for the treatment of diabetic neuropathic pain in adults. The company will seek clarification from the FDA of its position and of the additional information required to obtain final marketing approval. UCB confirmed that lacosamide (Vimpat) is also currently under active review by the FDA for the adjunctive treatment of partial onset seizures in patients with epilepsy, age 16 and over. Vimpat is also under review by the...

2008-07-21 03:00:16

By Anonymous Indianapolis-based Eli Lilly and Co., the world's largest maker of psychiatric drugs, has won U.S. regulatory approval to sell the drug Cymbalta for fibromyalgia. The U.S. Food and Drug Administration's clearance allows Lilly to sell Cymbalta for symptoms of fibromyalgia, a little-understood ailment that causes debilitating pain and fatigue. Cymbalta, which Lilly expects to be its top-selling drug in the United States this year, is also used to treat depression, anxiety and...

2008-06-17 09:01:13

Eli Lilly and Company has announced that the FDA has approved Cymbalta for the management of fibromyalgia, a chronic widespread pain disorder. Eli Lilly's Cymbalta is said to be the first serotonin-norepinephrine reuptake inhibitor with proven efficacy for reducing pain in patients with fibromyalgia. The fibromyalgia indication represents the second FDA-approved use for Cymbalta for a pain disorder, demonstrating the medication's analgesic effect. The approval marks the fourth disorder...

2007-08-10 06:04:23

The termination of Pristiq for fibromyalgia represents another setback for Wyeth, which had high hopes for its follow-on drug to Effexor. However, all is not lost as Wyeth's greatest commercial opportunity for Pristiq will be gained through indications for depression and menopausal symptoms, although heart and liver safety concerns added to regulatory delays may still limit the drug's potential. The development of Pristiq (desvenlafaxine succinate) for fibromyalgia was terminated during the...

2005-07-06 23:36:08

A report in the July Annals of Neurology describes a serious adverse event experienced by a participant in a clinical trial that may raise a new caution about the use of antiepileptic drugs for conditions other than epilepsy. An elderly women enrolled in a clinical trial of pregabalin, a new drug for the treatment of pain and seizures, abruptly discontinued the medication and then developed neurological symptoms including headache, confusion and hallucinations. The study's authors from...


Latest Pregabalin Reference Libraries

Generalized Anxiety Disorder
2013-07-25 15:07:54

Generalized Anxiety Disorder (GAD) is an anxiety disorder with worry about normal, everyday situations such as finance, health and wellbeing in relationships (personal and work related) all lasting longer than six months. Symptoms The symptoms of GAD can include but are not limited to difficulty swallowing, rashes, shortness of breath, fidgeting, headaches, tension, nausea, etc. In order for GAD to be ruled as present, the symptoms and feelings must be experiences for at least six...

More Articles (1 articles) »
Word of the Day
bodacious
  • Remarkable; prodigious.
  • Audacious; gutsy.
  • Completely; extremely.
  • Audaciously; boldly.
  • Impressively great in size; enormous; extraordinary.
This word is probably from the dialectal 'boldacious,' a blend of 'bold' and 'audacious.'
Related